RGTL.F Stock Overview
A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.36 |
52 Week High | AU$1.00 |
52 Week Low | AU$0.14 |
Beta | 1.05 |
11 Month Change | 56.49% |
3 Month Change | 46.94% |
1 Year Change | -40.00% |
33 Year Change | -99.00% |
5 Year Change | -98.69% |
Change since IPO | -99.10% |
Recent News & Updates
Recent updates
Shareholder Returns
RGTL.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 0.3% | 0.3% |
1Y | -40.0% | 23.6% | 38.3% |
Return vs Industry: RGTL.F underperformed the US Pharmaceuticals industry which returned 23.6% over the past year.
Return vs Market: RGTL.F underperformed the US Market which returned 38.3% over the past year.
Price Volatility
RGTL.F volatility | |
---|---|
RGTL.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.4% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGTL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RGTL.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Roby Zomer | argentbiopharma.com |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
RGTL.F fundamental statistics | |
---|---|
Market cap | US$12.66m |
Earnings (TTM) | -US$11.75m |
Revenue (TTM) | US$597.40k |
19.0x
P/S Ratio-1.0x
P/E RatioIs RGTL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGTL.F income statement (TTM) | |
---|---|
Revenue | AU$891.08k |
Cost of Revenue | AU$1.20m |
Gross Profit | -AU$304.15k |
Other Expenses | AU$17.23m |
Earnings | -AU$17.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.36 |
Gross Margin | -34.13% |
Net Profit Margin | -1,967.34% |
Debt/Equity Ratio | -149.0% |
How did RGTL.F perform over the long term?
See historical performance and comparison